We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
FUJIREBIO

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
18 Mar 2021 - 21 Mar 2021
13 Apr 2021 - 16 Apr 2021

NanoString Technology Modernizes Liposarcoma Diagnostics

By LabMedica International staff writers
Posted on 15 Feb 2021
Print article
Image: Atypical lipomatous tumor/well-differentiated liposarcoma (left-hand); lipoma (right-hand) (Photo courtesy of Dr.Tony Ng, The University of British Columbia)
Image: Atypical lipomatous tumor/well-differentiated liposarcoma (left-hand); lipoma (right-hand) (Photo courtesy of Dr.Tony Ng, The University of British Columbia)
A recently published study showed that a newer NanoString-based method could allow for more rapid and cost-efficient diagnosis of liposarcomas than the commonly used fluorescence in situ hybridization (FISH) method.

Liposarcoma is a rare type of cancer that arises in fat cells in soft tissue, such as that inside the thigh. It is typically a large, bulky tumor, and tends to have multiple smaller satellites that extend beyond the main confines of the growth. Several types of liposarcoma exist. While some grow slowly with the cells remaining localized to one area of the body, other types grow very quickly and may metastasize.

In addition to FISH, which is a relatively expensive as well as labor- and equipment-intensive technology, immunohistochemistry (IHC) is often used to diagnose liposarcoma. However, IHC is felt to be inaccurate and hard to interpret.

To modernize the diagnosis of liposarcoma, investigators at the University of British Columbia (Vancouver, Canada) examined whether the newer NanoString-based technology (Seattle, WA, USA) could allow for more rapid and cost-efficient diagnosis of liposarcomas on standard formalin-fixed tissues through gene expression. For this study, they used large-scale transcriptome data from The Cancer Genome Atlas. The Cancer Genome Atlas is a project, begun in 2005, to catalog genetic mutations responsible for cancer, using genome sequencing and bioinformatics. The Cancer Genome Atlas applies high-throughput genome analysis techniques to improve diagnosis, treatment, and prevention of cancer through a better understanding of the genetic basis of this disease.

Data extracted from The Cancer Genome Atlas identified 20 genes, most from the 12q13-15 amplicon, that distinguished de-differentiated liposarcoma from other sarcomas and could be measured within a single NanoString assay. A machine learning model was subsequently developed to determine the probability that a given sample was positive for liposarcoma and was then applied to 45 retrospective cases to determine boundaries for positive and negative predictions. The effectiveness of the assay was validated on an independent set of 100 sarcoma samples (including 40 incident prospective cases), where histologic examination was considered insufficient for clinical diagnosis.

Results revealed that the NanoString assay had a 93% technical success rate, and an accuracy of 97.8% versus the FISH gold standard. Furthermore, results from the NanoString assay were available in 36 hours, whereas it required from one to two weeks to obtain FISH results.

"Liposarcomas are a type of malignant cancer that is difficult to diagnose because, even under a microscope, it is hard to differentiate liposarcomas from benign tumors or other types of cancer that need different treatments," said senior author Dr. Torsten Owen Nielsen, clinician-scientist in the department of pathology and laboratory medicine at the University of British Columbia. "Many liposarcomas look like their benign and relatively common counterparts, lipomas. Diagnostic delay and uncertainty cause severe stress for patients, and misdiagnosis can have many consequences including delayed or inadequate treatment or unnecessary surgical procedures and long-term postoperative follow up."

The liposarcoma-Nanostring study was published in the December 23, 2020 online edition of The Journal of Molecular Diagnosis.

Related Links:
University of British Columbia
NanoString


Gold Supplier
SARS-CoV-2 (COVID-19) Antibody Test
INgezim COVID 19 CROM
SARS-CoV-2 & Influenza Test
cobas SARS-CoV-2 & Influenza A/B Test
DNA/RNA Extraction Kit
Exiprep 96 Lite & Viral DNA/RNA Kit
New
Silver Supplier
Nucleic Acid Extractor
Pre-NAT II

Print article

Channels

Industry

view channel
Illustration

Mindray and Tencent AI Lab to Jointly Develop AI Products for Blood Disease Screening and In Vitro Diagnosis

Shenzhen Mindray Biomedical Electronics Co., Ltd. (Shenzhen, China) has signed an AI cooperation framework agreement with Tencent AI Lab (Shenzhen, China) to jointly develop AI products for blood cell... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.